Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 4006 AL 4020

Every Cloud Has a Silver Lining: Proneurogenic Effects of Aβ Oligomers and HMGB-1 via Activation of the RAGE-NF-κB Axis

Bortolotto V, Grilli M.

CNS Neurol Disord Drug Targets. 2017;16(10):1066-1079. doi: 10.2174/1871527315666160803153459.

α-Melanocyte Stimulating Hormone as a Potential Therapy for Alzheimer`s Disease

Ma K, McLaurin J.

Curr Alzheimer Res. 2017;14(1):18-29. doi: 10.2174/1567205013666160819130641.

GABAergic Microcircuits in Alzheimer's Disease Models

Villette V, Dutar P.

Curr Alzheimer Res. 2017;14(1):30-39. doi: 10.2174/1567205013666160819125757.

Alzheimer's Drug Discovery Maze: A Snap View of the Past Decade's Diverse Pharmacological Targets for the Disorder

Sikazwe D, Yendapally R, Ramsinghani S, Khan M.

Mini Rev Med Chem. 2017;17(3):305-318. doi: 10.2174/1389557516666160822152625.

Role of Glutamate and NMDA Receptors in Alzheimer's Disease

Wang R, Reddy PH.

J Alzheimers Dis. 2017;57(4):1041-1048. doi: 10.3233/JAD-160763.

Novel Multitarget Hybrid Compounds for the Treatment of Alzheimer's Disease

Michalska P, Buendia I, Del Barrio L, Leon R.

Curr Top Med Chem. 2017;17(9):1027-1043. doi: 10.2174/1568026616666160927154116.

Multitarget Tacrine Hybrids with Neuroprotective Properties to Confront Alzheimer's Disease

Spilovska K, Korabecny J, Nepovimova E, Dolezal R, Mezeiova E, Soukup O, Kuca K.

Curr Top Med Chem. 2017;17(9):1006-1026. doi: 10.2174/1568026605666160927152728.

Targeting Tumor Necrosis Factor Alpha for Alzheimer's Disease

Decourt B, Lahiri DK, Sabbagh MN.

Curr Alzheimer Res. 2017;14(4):412-425. doi: 10.2174/1567205013666160930110551.

Neuroprotective and Neurotoxic Implications of α7 Nicotinic Acetylcholine Receptor and Aβ Interaction: Therapeutic Options in Alzheimer's Disease

Farhat SM, Ahmed T.

Curr Drug Targets. 2017;18(13):1537-1544. doi: 10.2174/1389450117666161005145143.

AZD3293: Pharmacokinetic and Pharmacodynamic Effects in Healthy Subjects and Patients with Alzheimer's Disease

Cebers G, Alexander RC, Haeberlein SB, Han D, Goldwater R, Ereshefsky L, Olsson T, Ye N, Rosen L, Russell M, Maltby J, Eketjäll S, Kugler AR.

J Alzheimers Dis. 2017;55(3):1039-1053. doi: 10.3233/JAD-160701.

Phytochemicals in the Treatment of Alzheimer's Disease: A Systematic Review

D'Onofrio G, Sancarlo D, Ruan Q, Yu Z, Panza F, Daniele A, Greco A, Seripa D.

Curr Drug Targets. 2017;18(13):1487-1498. doi: 10.2174/1389450117666161102121553.

Protective Effects of Caffeic Acid and the Alzheimer's Brain: An Update

Habtemariam S.

Mini Rev Med Chem. 2017;17(8):667-674. doi: 10.2174/1389557516666161130100947.

Research update on Alzheimer's disease and introduction to the Expert Review of Neurotherapeutics special issue

Gauthier S.

Expert Rev Neurother. 2017 Jan;17(1):1-2. doi: 10.1080/14737175.2017.1268054.

Serotonin 5-HT(6) Receptor Antagonists in Alzheimer's Disease: Therapeutic Rationale and Current Development Status

Ferrero H, Solas M, Francis PT, Ramirez MJ.

CNS Drugs. 2017 Jan;31(1):19-32. doi: 10.1007/s40263-016-0399-3.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias